NanoVibronix Stock (NASDAQ:NAOV)


RevenueOwnershipFinancialsChart

Previous Close

$1.88

52W Range

$1.05 - $162.50

50D Avg

$4.70

200D Avg

$15.96

Market Cap

$1.51M

Avg Vol (3M)

$86.23K

Beta

2.06

Div Yield

-

NAOV Company Profile


NanoVibronix, Inc., operating through its subsidiary NanoVibronix Ltd., develops and commercializes innovative, non-invasive devices that stimulate biological responses for therapeutic purposes. Their core focus areas include mitigating biofilm formation, accelerating wound repair, and alleviating pain. Key among their product line is UroShield, an ultrasound-based solution engineered to deter bacterial colonization and biofilm development in urinary catheters, thereby boosting antibiotic efficacy and reducing associated patient discomfort. They also offer PainShield and WoundShield, both patch-based therapeutic ultrasound technologies. PainShield targets relief from pain, muscle spasms, and joint contractures, while WoundShield is designed to foster tissue regeneration and promote healing in wounds. The company distributes these products directly to consumers and via extensive distributor networks spanning the United States, Israel, Europe, India, and numerous other international regions. Founded in 2003, NanoVibronix, Inc. maintains its corporate headquarters in Elmsford, New York.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

31

IPO Date

May 28, 2015

Website

NAOV Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
UNITED STATES$2.51M$2.16B-
Australia/New Zealand$20.00K--
Europe$8.00K$17.00K$101.00M
Other Country$15.00K$46.00K-
ISRAEL-$4.00K$1.00M
AUSTRALIA-$29.00K$19.00M
NEW ZEALAND-$12.00K-

Fiscal year ends in Dec 25 | Currency in USD

NAOV Financial Summary


Dec 25Dec 24Dec 23
Revenue$2.55M$2.56M$2.28M
Operating Income$-22.89M$-3.58M$-3.44M
Net Income$-18.18M$-3.71M$-3.71M
EBITDA$-22.89M$-3.69M$-3.55M
Basic EPS$-28.93$-13.73$-21.20
Diluted EPS$-28.93$-13.73$-21.20

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison


TickerCompany
AMIXAutonomix Medical, Inc. Common Stock
VEROVenus Concept Inc.
GRIGRI Bio, Inc.
ACONAclarion, Inc.
BBLGBone Biologics Corporation
CNSPCNS Pharmaceuticals, Inc.
NDRAENDRA Life Sciences Inc.
MOVECorvex, Inc.
BJDXBluejay Diagnostics, Inc.
HSCSHeartSciences Inc.